IAVI Awarded $36 Million From BARDA for Bundibugyo Virus Vaccine Development
Initial award funds process development, manufacturing, and clinical evaluation of a single-dose vaccine candidate through strategic partnerships with Hilleman Laboratories, SK bioscience, and IDT Biologika NEW YORK, NY, SINGAPORE, SG INCHEON, SOUTH KOREA, AND DESSAU-ROSSLAU, DE / ACCESS Newswire / October 28, 2026 / Today IAVI, a global nonprofit biomedical